(Q34038788)

30 July 2017

1 reference

title

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma (English)

1 reference

30 July 2017

Schadendorf D

1

1 reference

30 July 2017

Paschen A

series ordinal

2

1 reference

30 July 2017

Sun Y

series ordinal

3

1 reference

30 July 2017

publication date

1 September 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

74

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

67-74

1 reference

Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Direct evidence to support the immunosurveillance concept in a human regressive melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Role of Interferons in the Thearpy of Melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Overview of melanoma vaccines: active specific immunotherapy for melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Vaccine therapy for malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Cell-based vaccination against melanoma--background, preliminary results, and perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Active-specific immunotherapy for melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Association of HLA phenotype with response to active specific immunotherapy of melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Relationship between immune response to melanoma vaccine immunization and clinical outcome in stage II malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Improved survival of patients with melanoma with an antibody response to immunization to a polyvalent melanoma vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: a clinical phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

A Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

A phase-I clinical study of autologous tumor cells plus interleukin-2-gene-transfected allogeneic fibroblasts as a vaccine in patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

1 reference

7 January 2021

Dendritic cells and the control of immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Proliferating dendritic cell progenitors in human blood

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Exposing the immunology of naked DNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Immunization with dendritic cells breaks immunodominance in CTL responses against minor histocompatibility and synthetic peptide antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Recombinant Listeria monocytogenes cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Molecular and cell biological aspects of infection by Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Oral somatic transgene vaccination using attenuated S. typhimurium.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Bacterial CpG DNA activates immune cells to signal infectious danger.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Multiple tumour-specific antigens expressed on a single tumour cell

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Abrogation of metastatic properties of tumour cells by de novo expression of H–2K antigens following H–2 gene transfection

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Antitumor effect of locally produced CD95 ligand

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Mechanisms responsible for signaling and functional defects.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

In situ analysis of transforming growth factor-beta s (TGF-beta 1, TGF-beta 2, TGF-beta 3), and TGF-beta type II receptor expression in malignant melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

Immune stimulatory potential of B7.1 and B7.2 retrovirally transduced melanoma cells: suppression by interleukin 10.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-2478%2800%2900251-0

7 January 2021

10.1016/S0165-2478(00)00251-0

Identifiers

DOI

1 reference

30 July 2017

1 reference